What happened in this Health story?

Patient and consumer representatives on FDA advisory committees frequently hold undisclosed ties to advocacy groups funded by pharmaceutical companies, including the drugmakers whose products are under review, a Health Affairs Scholar analysis found.

What is a key fact in this story? (1)

**A Health Affairs Scholar analysis** found that nearly 40% of FDA advisory committee meetings over a recent 20-year period included a patient or consumer representative with active ties to an advocacy group funded by pharmaceutical companies.

What is a key fact in this story? (2)

**Several committees** saw the share of patient or consumer reps with pharma-linked affiliations exceed 50% of their meetings during the period studied.

📎 SkimNews has covered FDA 85+ times · see the file →

40% of FDA panel meetings had pharma-linked patient reps — SkimNews

By STAT News · Summarized & edited by Kapil Samant · 2026-10-13

Get the Health newsletter

Daily health & science — research, biotech, public health, the studies worth knowing. Free.

A Health Affairs Scholar analysis found that nearly 40% of FDA advisory committee meetings over a recent 20-year period included a patient or consumer representative with active ties to an advocacy group funded by pharmaceutical companies.
Several committees saw the share of patient or consumer reps with pharma-linked affiliations exceed 50% of their meetings during the period studied.
More than one in 10 advisory committee meetings included a representative affiliated with an organization that received funding from the drugmaker whose medicine was under review.
Most of these organizational ties between reps and pharma-funded advocacy groups were not disclosed during the meetings, raising questions about voting behavior, the analysis noted.
FDA conflict-of-interest policies are well-established for scientific committee members, yet policies governing patient and consumer reps—particularly around industry funding of advocacy groups—remain underdeveloped.

Why it matters: FDA advisory committees help shape drug approval decisions, yet more than one in 10 meetings included a rep tied to the drugmaker whose product was under review. The analysis flags a clear policy gap: conflict-of-interest rules cover scientists but not patient and consumer reps, leaving most organizational ties undisclosed.